169 related articles for article (PubMed ID: 34389740)
1. Potent antitumor activity of a glutamyltransferase-derived peptide via an activation of oncosis pathway.
Fang C; Li W; Yin R; Zhu D; Liu X; Wu H; Wang Q; Wang W; Bai Q; Chen B; Yao X; Chen Y
Sci Rep; 2021 Aug; 11(1):16507. PubMed ID: 34389740
[TBL] [Abstract][Full Text] [Related]
2. Dehydroabietic acid derivative QC2 induces oncosis in hepatocellular carcinoma cells.
Zhang G; Jiang C; Wang Z; Chen W; Gu W; Ding Y
Biomed Res Int; 2014; 2014():682197. PubMed ID: 25110686
[TBL] [Abstract][Full Text] [Related]
3. Low-density lipoprotein docosahexaenoic acid nanoparticles induce ferroptotic cell death in hepatocellular carcinoma.
Ou W; Mulik RS; Anwar A; McDonald JG; He X; Corbin IR
Free Radic Biol Med; 2017 Nov; 112():597-607. PubMed ID: 28893626
[TBL] [Abstract][Full Text] [Related]
4. CHM-1, a novel synthetic quinolone with potent and selective antimitotic antitumor activity against human hepatocellular carcinoma in vitro and in vivo.
Wang SW; Pan SL; Huang YC; Guh JH; Chiang PC; Huang DY; Kuo SC; Lee KH; Teng CM
Mol Cancer Ther; 2008 Feb; 7(2):350-60. PubMed ID: 18281518
[TBL] [Abstract][Full Text] [Related]
5. CD8
Xu C; Lu X; Liu W; Chen A; Meng G; Zhang H; Li B; Zhang Y; Wu J; Wei J
J Transl Med; 2018 May; 16(1):132. PubMed ID: 29784005
[TBL] [Abstract][Full Text] [Related]
6. Benzylidene-indolinones are effective as multi-targeted kinase inhibitor therapeutics against hepatocellular carcinoma.
Ho HK; Chua BT; Wong W; Lim KS; Teo V; Ong HT; Chen X; Zhang W; Hui KM; Go ML; Ullrich A
Mol Oncol; 2014 Oct; 8(7):1266-77. PubMed ID: 24839937
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.
Nishina S; Yamauchi A; Kawaguchi T; Kaku K; Goto M; Sasaki K; Hara Y; Tomiyama Y; Kuribayashi F; Torimura T; Hino K
Cell Mol Gastroenterol Hepatol; 2019; 7(1):115-134. PubMed ID: 30510994
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis.
Saeki I; Terai S; Fujisawa K; Takami T; Yamamoto N; Matsumoto T; Hirose Y; Murata Y; Yamasaki T; Sakaida I
J Gastroenterol; 2013 Jun; 48(6):738-50. PubMed ID: 23011081
[TBL] [Abstract][Full Text] [Related]
9. The aryl hydrocarbon receptor ligand ITE inhibits cell proliferation and migration and enhances sensitivity to drug-resistance in hepatocellular carcinoma.
Zhang X; He B; Chen E; Lu J; Wang J; Cao H; Li L
J Cell Physiol; 2021 Jan; 236(1):178-192. PubMed ID: 32510618
[TBL] [Abstract][Full Text] [Related]
10. Aptamer-functionalized peptide H3CR5C as a novel nanovehicle for codelivery of fasudil and miRNA-195 targeting hepatocellular carcinoma.
Liu Y; Wu X; Gao Y; Zhang J; Zhang D; Gu S; Zhu G; Liu G; Li X
Int J Nanomedicine; 2016; 11():3891-905. PubMed ID: 27574422
[TBL] [Abstract][Full Text] [Related]
11. Recombinant vascular basement-membrane-derived multifunctional peptide inhibits angiogenesis and growth of hepatocellular carcinoma.
Wu YH; Cao JG; Xiang HL; Xia H; Qin Y; Huang AJ; Xiao D; Xu F
World J Gastroenterol; 2009 Apr; 15(14):1744-50. PubMed ID: 19360918
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
13. 6H2L, a novel synthetic derivative of bifendate, induces apoptosis in hepatoma cells via mitochondrial and MAPK pathway.
Yu L; Wang F; Tai M; Li J; Gong S; Zhou Z; Yin X; Gu X; Li C
Eur J Pharmacol; 2020 Sep; 882():173299. PubMed ID: 32589884
[TBL] [Abstract][Full Text] [Related]
14. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P
J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062
[TBL] [Abstract][Full Text] [Related]
15. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
16. T7 peptide cytotoxicity in human hepatocellular carcinoma cells is mediated by suppression of autophagy.
Liu F; Wang F; Dong X; Xiu P; Sun P; Li Z; Shi X; Zhong J
Int J Mol Med; 2019 Aug; 44(2):523-534. PubMed ID: 31173192
[TBL] [Abstract][Full Text] [Related]
17. A Novel Microtubule-Disrupting Agent Induces Endoplasmic Reticular Stress-Mediated Cell Death in Human Hepatocellular Carcinoma Cells.
Ho CT; Chang YJ; Yang LX; Wei PL; Liu TZ; Liu JJ
PLoS One; 2015; 10(9):e0136340. PubMed ID: 26355599
[TBL] [Abstract][Full Text] [Related]
18. Autophagy activation in hepatocellular carcinoma contributes to the tolerance of oxaliplatin via reactive oxygen species modulation.
Ding ZB; Hui B; Shi YH; Zhou J; Peng YF; Gu CY; Yang H; Shi GM; Ke AW; Wang XY; Song K; Dai Z; Shen YH; Fan J
Clin Cancer Res; 2011 Oct; 17(19):6229-38. PubMed ID: 21825039
[TBL] [Abstract][Full Text] [Related]
19. VI-16, a newly synthesized flavonoid, induces apoptosis through the mitochondrial pathway in human hepatoma cells.
Lu N; Wei L; Gong D; Gao Y; Dai Q; Li Z; Guo Q
Oncol Rep; 2012 Mar; 27(3):873-9. PubMed ID: 22179765
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinoma-targeted drug discovery through image-based phenotypic screening in co-cultures of HCC cells with hepatocytes.
Jang JW; Song Y; Kim KM; Kim JS; Choi EK; Kim J; Seo H
BMC Cancer; 2016 Oct; 16(1):810. PubMed ID: 27756242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
